Browse the evidence

Higher circulating estrogen levels in women are predictive of increased rates of nausea and vomiting when taking GLP-1 receptor agonists, and estrous cycle phase modulates drug sensitivity in female mice.

Your risk of side effects from GLP-1 drugs may fluctuate with your menstrual cycle, peaking when estrogen is highest. While this paper used mice, human data suggests higher estrogen levels correlate with more nausea. Tracking your cycle might help you and your doctor anticipate and manage side effects.

Daily supplementation with 0.6 g/kg body weight of whey protein does not enhance body composition, core muscle endurance, or joint flexibility adaptations in trained women performing 10 weeks of Pilates training, despite increasing total daily protein intake to ~1.78 g/kg.

If you are a trained woman doing Pilates regularly, adding whey protein supplements on top of your normal diet will not make you lose more fat, gain more muscle, or improve your flexibility compared to just doing the training. Focus on consistent training and adequate whole-food protein intake rather than buying supplements.

Males in the US have consistently higher diabetes incidence and prevalence than females across all age groups, with a significant disparity that becomes more pronounced in older cohorts.

Men in the US are diagnosed with diabetes more often than women, and this gap widens with age. This may be partly due to biological factors and partly due to less frequent healthcare engagement. Men should prioritize regular screening and not delay care due to cultural norms.

The Behavioral Change Technique 'Instruction on how to perform behaviour' is associated with weight GAIN (mean weight change +2.53 kg) rather than loss, suggesting it may be counterproductive in brief, opportunistic primary care advice.

Avoid using 'Instruction on how to perform behaviour' (like handing out leaflets or directing to websites) as a primary strategy in brief weight loss advice. This study found it was associated with weight gain, likely because it is used as a 'simple way to intervene' with patients who are less ready to change. Instead, focus on motivational feedback and follow-up.

Low baseline ribosome-related gene expression and resistance training-induced declines in ribosome-related gene expression are associated with greater skeletal muscle hypertrophy in young men and women.

If you are struggling to build muscle despite consistent resistance training, your baseline cellular machinery (ribosomes) might be a limiting factor, but this is largely genetic or determined by prior activity levels. The key takeaway is that 'more' isn't always 'better' for muscle growth; your body may adapt by becoming more efficient with what it has rather than expanding its capacity. Focus on progressive overload and consistency, as the body's response is individual and not strictly dictated by having the highest possible baseline ribosome levels.

Usual intakes of animal and plant protein are not adversely associated with all-cause, cardiovascular disease, or cancer-related mortality risk in adults.

You do not need to restrict your protein intake, whether from animal or plant sources, to avoid increasing your risk of death from all causes, heart disease, or cancer. The data suggests that typical protein intakes within recommended ranges are safe and not linked to higher mortality.

GLP-1RA treatment induces distinct molecular changes in skeletal muscle proteome (upregulation of mitochondrial proteins) compared to calorie restriction, despite similar weight loss and muscle mass changes.

This finding is primarily mechanistic and suggests GLP-1s may improve muscle metabolic efficiency (mitochondrial function) beyond just weight loss, though this does not currently translate to a specific user action beyond standard treatment.

GLP-1 receptor agonists and MC4R modulators are emerging therapeutic strategies that target hypothalamic pathways to treat metabolic diseases.

Current treatments for obesity and diabetes, such as GLP-1 receptor agonists, work by targeting specific pathways in the hypothalamus. This highlights the importance of central nervous system mechanisms in these conditions and supports the use of these medications as effective treatments.

GLP-1 receptor agonists slow renal disease progression and reduce albuminuria in patients with diabetic kidney disease, although evidence is less robust than for SGLT2 inhibitors.

If you have diabetic kidney disease, GLP-1 receptor agonists may help slow kidney damage and reduce protein in your urine. While there is less data on their kidney benefits compared to SGLT2 inhibitors, they are still considered valuable. Discuss with your doctor if they are appropriate for you, especially if you have cardiovascular risks.

Orforglipron is associated with a dose-dependent increase in gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) and treatment discontinuation rates, particularly at doses of 12 mg and higher.

While effective, orforglipron often causes stomach problems like nausea, vomiting, and diarrhea, especially at higher doses (12 mg and above). These side effects are the main reason people stop taking the medication. Patients should be aware that higher doses provide more weight loss but also carry a higher risk of stopping treatment due to discomfort. Starting at a lower dose and titrating slowly may help manage these side effects.

Discontinuing or interrupting GLP-1 receptor agonist (GLP-1RA) treatment progressively erodes cardiovascular protection, with longer durations of non-use associated with a graded increase in the risk of major adverse cardiovascular events (MACE).

If you have Type 2 Diabetes and take a GLP-1RA (like Ozempic or Wegovy), your heart protection is tied to continuous use. Stopping the medication does not leave you in a 'safe' state; it actively increases your risk of heart attack or stroke, and the longer you stay off the drug, the higher that risk becomes. If you must stop due to side effects or cost, do not just stop abruptly; consult your provider for a strategy to manage the increased cardiovascular risk during the transition.

Standard-of-care weight management in primary care is characterized by extremely low rates of active treatment, with only 12% of eligible patients receiving a weight-prioritized visit and less than 6% receiving any weight-related referral or anti-obesity drug prescription.

If you have a BMI over 25, do not assume your regular doctor is actively treating your weight. In standard practice, most patients like you are not getting referrals or medications. You must explicitly request a 'weight-prioritized visit' or ask for specific interventions (referrals, medications) to break through the system's inertia.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) do not increase the risk of thyroid or pancreatic cancer in humans, despite animal model concerns.

If you are prescribed a GLP-1 agonist like semaglutide or liraglutide, you do not need to worry about an increased risk of thyroid or pancreatic cancer based on current human data. The FDA warning is based on animal studies, and large human trials have not confirmed this risk.

Bariatric surgery reduces the overall incidence and mortality of cancer, with a more pronounced effect in women than men.

Bariatric surgery is a highly effective intervention for reducing the risk of cancer and cancer-related mortality in people with obesity. The benefit is particularly strong for women, likely due to the reduction in hormone-dependent cancers. The risk reduction is directly linked to the amount of weight lost.

Pharmacological inhibition or genetic deletion of the melanocortin-3 receptor (MC3R) enhances the anorectic and weight-loss efficacy of GLP-1 receptor agonists (e.g., liraglutide, semaglutide, tirzepatide) without increasing malaise or peripheral incretin effects.

Current research indicates that blocking the MC3R receptor can make GLP-1 weight loss drugs (like Ozempic or Wegovy) work better, allowing for lower doses to achieve the same weight loss. This happens without increasing the nausea or stomach upset often associated with these drugs. However, effective MC3R-blocking drugs that can cross into the brain are not yet widely available for human use.

MC3R inhibition generalizes to enhance sensitivity to other anorectic hormones, including leptin, peptide YY (PYY3-36), and cholecystokinin (CCK).

Blocking the MC3R receptor doesn't just help GLP-1 drugs; it may also make your body's natural satiety signals (like leptin and gut hormones) work more effectively. This suggests a broader benefit for appetite control beyond just one drug class.

Free leucine supplementation (6g/day split into 3g pre- and post-exercise) does not improve muscle recovery or reduce markers of muscle damage following resistance exercise in untrained young adults consuming adequate dietary protein.

If you are a young, untrained individual eating enough protein (over 1.2g per kg of body weight daily), taking 6 grams of leucine around your workout will not help you recover faster, reduce soreness, or build muscle compared to just eating your normal diet. Save your money on leucine supplements; focus on getting enough total protein and completing your resistance training.

High-sensitivity ELISA assays are required to detect exercise-induced reductions in fasting insulin, whereas standard automated immunoassays (e.g., Immulite 2000) fail to capture these changes despite high correlation with international standards.

If you are tracking insulin response to lifestyle changes (like exercise or diet), ensure your laboratory uses a high-sensitivity ELISA assay. Standard automated immunoassays may report 'normal' or unchanged insulin levels even when significant metabolic improvements have occurred, leading to a false conclusion that the intervention is ineffective.

Current clinical-metabolomic biomarkers (including BCAA and lipid profiles) cannot predict individual changes in insulin sensitivity following lifestyle interventions, despite their ability to correlate with baseline insulin levels.

Do not rely on current commercial metabolomic tests (like BCAA or detailed lipid panels) to predict whether you will lose weight or improve insulin sensitivity through exercise. These tests may tell you your current risk status, but they cannot tell you how your body will respond to a specific lifestyle change.

SGLT2 inhibitors (specifically empagliflozin and canagliflozin) provide significant cardiovascular benefits, particularly reducing cardiovascular death and heart failure hospitalizations, primarily through hemodynamic mechanisms like intravascular volume reduction, with efficacy potentially modified by the duration of diabetes.

If you have Type 2 Diabetes and existing heart issues, ask your doctor about SGLT2 inhibitors like empagliflozin. They have been proven to significantly reduce the risk of dying from heart causes and hospitalizations for heart failure, likely by reducing fluid volume in the body. This benefit is most pronounced in patients with established cardiovascular disease.

Intensive glycemic control reduces cardiovascular mortality only in patients with early-stage diabetes (duration <10-15 years), whereas it may increase mortality in patients with long-standing diabetes.

If you have had Type 2 Diabetes for many years (over 10), aiming for very low blood sugar levels might actually increase your risk of death due to side effects like severe hypoglycemia. Focus on stable control rather than aggressive lowering. If you have recently been diagnosed, aggressive control can provide long-term 'legacy' protection for your heart.

Obesity directly causes chronic kidney disease (CKD) and end-stage renal disease (ESRD) through compensatory hyperfiltration, intraglomerular hypertension, and direct adipose tissue endocrine effects, independent of diabetes and hypertension.

High body weight, particularly visceral fat, directly stresses the kidneys through increased pressure and inflammatory signals, leading to chronic kidney disease even without diabetes. Managing weight through lifestyle changes is a primary strategy to prevent kidney damage.

High consumption of artificially-sweetened beverages (ASBs) is not significantly associated with increased cardiovascular disease risk in physically active individuals.

If you are physically active, drinking two or more artificially-sweetened beverages a day does not appear to increase your cardiovascular disease risk in this study. However, this does not mean they are 'healthy,' and they should not be relied upon as a primary health strategy.

The enteric nervous system (ENS) directly senses luminal nutrients (glucose, fatty acids, amino acids) via specific receptors and ion channels on enteric neurons, independent of enteroendocrine cell intermediaries.

Your gut has its own nervous system that directly senses nutrients like glucose and fats, not just through hormones but through direct neural pathways. This 'second brain' communicates with your central brain to regulate hunger and satiety. Understanding this can help explain why certain foods trigger immediate physiological responses and why gut health is crucial for metabolic regulation.